SCHEMBL1521567

SCHEMBL1521567

CN1C(=O)N(c2ccc(F)c(N)c2)Cc2cnc(N)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 11/20 0.47
FGFR1 P11362 4/20 0.43
KDR P35968 4/20 0.43
FGFR3 P22607 3/20 0.43
KIT P10721 3/20 0.43
BMX P51813 2/20 0.43
LCK P06239 2/20 0.43
SRC P12931 2/20 0.43
PDGFRB P09619 2/20 0.43
ABL1 P00519 1/20 0.43
FES P07332 1/20 0.43
RET P07949 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT1 P17948 1/20 0.43
EPHA3 P29320 1/20 0.43
EPHB4 P54760 1/20 0.43
TEK Q02763 1/20 0.43
TNK2 Q07912 1/20 0.43
MAP4K2 Q12851 1/20 0.43
KARS1 Q15046 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521723 0.87 FGFR4 (0.66) FGFR4FGFR1KDRFGFR3KIT
SCHEMBL1521532 0.87 FGFR4 (0.50) FGFR4BMXABL1TNK2MAP4K2
SCHEMBL1521505 0.84 FGFR4 (0.40) FGFR4FGFR1KDRFGFR3KIT
SCHEMBL1521503 0.80 FGFR4 (0.39) FGFR4FGFR1KDRFGFR3KIT
SCHEMBL1521677 0.78 FGFR1 (0.38) FGFR4FGFR1KDRFGFR3KIT
SCHEMBL1521384 0.76 FGFR1 (0.37) FGFR4FGFR1KDRFGFR3KIT
SCHEMBL1521763 0.75 ABL1 (0.43) FGFR1KDRFGFR3KITBMX
SCHEMBL1521729 0.73 FGFR4 (0.49) FGFR4FGFR1KDRFGFR3KIT
SCHEMBL1521434 0.73 FGFR4 (0.38) FGFR4FGFR1KDRFGFR3PDGFRB
SCHEMBL1522002 0.73 FGFR4 (0.49) FGFR4FGFR1FGFR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR4 1073/4885FGFR1 577/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.